Concentration of low-density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation

Dyslipidemia is a frequent side effect associated with nilotinib treatment. Patients with chronic myeloid leukemia (CML) under treatment with nilotinib who develop dyslipidemia have been shown to have a higher risk of presenting atherosclerotic cardiovascular disease (ACVD). Therapeutic discontinuat...

Descripción completa

Detalles Bibliográficos
Autores principales: Roa-Chamorro, Ricardo, Puerta-Puerta, José Manuel, Torres-Quintero, Lucía, Jaén-Águila, Fernando, González-Bustos, Pablo, Rodríguez-Gil, Miguel Ángel, Mediavilla-García, Juan Diego
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361990/
https://www.ncbi.nlm.nih.gov/pubmed/37479802
http://dx.doi.org/10.1038/s41598-023-39057-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361990/
https://www.ncbi.nlm.nih.gov/pubmed/37479802
http://dx.doi.org/10.1038/s41598-023-39057-x

Ejemplares similares